A novel class of antibiotics for treatment of infected atopic dermatitis: an innovative solution for a significant unmet medical need

Project Information

ATx201

Grant agreement ID: 736508

DOI

10.3030/736508

Project closed

EC signature date 11 July 2016

Start date 1 August 2016

End date 30 November 2016

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

UNION THERAPEUTICS AS
Denmark

Periodic Reporting for period 1 - ATx201 (A novel class of antibiotics for treatment of infected atopic dermatitis: an innovative solution for a significant unmet medical need)

Reporting period: 2016-08-01 to 2016-11-30

Summary of the context and overall objectives of the project

Atopic dermatitis (AD) is associated with significant co-morbidity. The solution provided by AntibioTx represents a new mode of action. The objectives of the project are to verify the promise of the drug product and advance commercial understanding to bring the solution to market.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The current stage of development of the proposed solution aligns with a Technology Readiness Level 7 since the drug compound had been tested on human subject volunteers. The project helped to establish the definition development plans for the solution in questions. This includes assessment of regulatory route, interaction with regulatory consultants and competent authorities, as well as clinical study design to bring forward its market authorisation agenda. This process has been developed with clinical advisors and KOLs within dermatology.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The project is designed to demonstrate how the solution in question can contribute to address the medical need in atopic dermatitis and offer a better treatment due to the new mode of action. Early data provides evidence for the potential to change the treatment paradigm of dermatological diseases by providing an innovative and significantly differentiated treatment.

fotolia-114431753-subscription-monthly-m.jpg

boksbillede1.jpg